Table 2.
Participant demographics and characteristics
| Ritonavir (n=10) | Efavirenz (n=10) | |
|---|---|---|
| Age (yrs) | 43.0 (2.6)1 | 43.5 (2.7) |
| Female | 1 (10%)2 | 1 (10%) |
| Race: | ||
| African-American | 2 (20%) | 4 (40%) |
| Caucasian | 4 (40%) | 6 (60%) |
| Hispanic | 4 (40%) | 0 (0%) |
| Current Substance Use Disorders: | ||
| Cocaine Abuse | 1 (10%) | 2 (20%) |
| Methamphetamine Abuse | 0 (0%) | 1 (10%) |
| Cannabis Abuse | 1 (10%) | 1 (10%) |
| Alcohol Abuse | 1 (10%) | 1 (10%) |
| Nicotine Dependence | 1 (10) | 0 (0%) |
| Current Alcohol Use (drinks/week) | 7.7 (2.8) | 6.9 (2.4) |
| Current Nicotine Use (cigarettes/day) | 4.6 (2.0) | 0.7 (0.4) |
| Laboratory Values Pre ART: | ||
| ALT (U/L) | 44 (11.2) | 27 (3.3) |
| AST (U/L) | 45 (8.0) | 30 (3.4) |
| HIV Viral Load (copies/mL) | ||
| Mean | 72,948 | 33,423 |
| Median | 17,674 | 15,225 |
| Range | 109 - 394,578 | 0 - 168,067 |
| CD4 Count (mm3) | ||
| Mean | 312 | 376 |
| Median | 303 | 372 |
| Range | 119 - 592 | 85 - 838 |
| Laboratory Values Post ART: | ||
| ALT (U/L) | 68 (26.0) | 32 (6.0) |
| AST (U/L) | 61 (19.1) | 28 (3.2) |
| HIV Viral Load (copies/mL) | ||
| Mean | 799 | 149 |
| Median | 125 | 64 |
| Range | 0 - 4985 | 0 - 720 |
| CD4 Count (mm3) | ||
| Mean | 396 | 367 |
| Median | 382 | 294 |
| Range | 106 - 733 | 133 - 697 |
| Hepatitis B (lifetime) | 1 (10%) | 5 (50%) |
| Hepatitis C | 3 (30%) | 1 (10%) |
|
| ||
| Other Diagnoses | Chronic Pain | |
| Neuropathy | ||
| Hypertension | ||
| Hyperlipidemia | ||
| Dysthymia | ||
1
mean (SE)
2
number (percent of sample)